AAP
RVMD icon

Aristotle Atlantic Partners’s Revolution Medicines RVMD Stock Holding History

Aristotle Atlantic Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$981K Sell
5,237
-6,399
-55% -$935K 0.04% 89
2026
Q1 		$1.13M Buy
11,636
+1,226
+12% +$124K 0.05% 83
2025
Q4 		$829K Buy
+10,410
New +$683K 0.04% 81

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Aristotle Atlantic Partners's RVMD Position: Q2 2026 in Review

Aristotle Atlantic Partners reduced its Revolution Medicines (RVMD) stake by 55% in Q2 2026, selling an estimated $935K and leaving 5,237 shares worth $981K. The position accounts for 0.04% of the portfolio, ranked #89.

Aristotle Atlantic Partners first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.13M in Q1 2026. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Aristotle Atlantic Partners held 5,237 shares of Revolution Medicines worth $981K as of Q2 2026.
  • Aristotle Atlantic Partners sold 6,399 Revolution Medicines shares in Q2 2026, an estimated $935K.
  • Revolution Medicines made up 0.04% of Aristotle Atlantic Partners's portfolio in Q2 2026, its #89 holding.
  • Aristotle Atlantic Partners first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • Aristotle Atlantic Partners's Revolution Medicines position peaked at $1.13M in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2026, filed 14 Aug 2026.